Evidence from two large prospective cohorts: variations in remnant cholesterol inflammation index and the risk of cardiometabolic multimorbidity in middle-aged and elderly populations.
A new blood marker combining cholesterol and inflammation measures independently predicts heart disease and metabolic illness risk across diverse populations.
In 8,165 participants from two large independent longitudinal cohorts (CHARLS China and ELSA UK), a novel composite Remnant Cholesterol Inflammation Index (RCII) independently predicted cardiometabolic multimorbidity incidence with consistent effects across populations and time-varying exposure patterns. RCII demonstrated moderate incremental predictive value over either remnant cholesterol or hs-CRP alone, suggesting potential as an integrated cardiometabolic risk biomarker.
What the study was
- Study design
- prospective_cohort
- Population
- Middle-aged and elderly adults in CHARLS (China, n=5870) and ELSA (UK, n=2295) cohorts
- Sample size
- 8165
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Diabetes Res Clin Pract
Why it surfaced
Robust dual-cohort validation of a clinically deployable composite biomarker addressing the convergence of lipid and inflammatory risk; directly relevant to the cardiometabolic watchlist and potentially actionable for integrated CV-metabolic risk stratification in clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.